NAME

Question types


Start with


Question limit

of 50 available terms

Print test

46 Matching questions

  1. Lisdexamfetamine brand name?
  2. TCAs are considered ____ line treatment for ADHD.
  3. Stimulant pharmacological therapy (5 options)
  4. Which mineral supplements are recommended in patient with ADHD?
  5. Central Alpha-2 adrenergic agonist MOA?
  6. Amoxetine MOA?
  7. T/F: Bupropion is FDA approved for the treatment of ADHD?
  8. Benefits to once-daily stimulant formulations.
  9. Onset of symptoms must occur before _____.
  10. What pharmacological therapy is considered first line?
  11. What are the 3 types of ADHD?
  12. T/F: TCAs have the highest risk of cardiac side effects?
  13. There is a universal belief that avoidance of ____ and ____ improves ADHD symptoms.
  14. Non-stimulant pharmacological therapy for ADHD (5 options)
  15. Diet treatment for ADHD?
  16. What class are ADHD medication?
  17. Bupropion MOA?
  18. TCAs used in the treatment of ADHD?
  19. Besides medications, it is important for patients with ADHD to undergo _______.
  20. How many symptoms of hyperactivity/impulsivity are needed for a diagnosis?
  21. Bupropion brand name
  22. Which pharmacological therapy is considered second line?
  23. Psych. adverse effects of stimulants.
  24. ADHD is characterized by the DSM-V with 2 main things.
  25. Non-pharmacologic therapy for ADHD?
  26. Adverse effects of amoxetine?
  27. Cardiac adverse effects of stimulants
  28. Side effects of guanfacine/ clonidine?
  29. What is considered the best option for treatment for a patient with ADHD?
  30. Which form of stimulants are the preferred treatment?
  31. MOA for methylphenidate and amphetamines?
  32. Bupropion adverse effects?
  33. Lisdexamfetamine advantages?
  34. Stimulants are considered to be ______ over psychotherapy.
  35. Amoxetine brand name?
  36. First degree relatives of an individual with ADHD are _____ times more likely to have ADHD.
  37. The AAP considers ADHD a _____ disease, and this by definition has _____.
  38. How many symptoms of inattention are needed for a diagnosis?
  39. Drugs that are central alpha-2 adrenergic agonists (2)
  40. Non-stimulant drug approved for use in ADHD in adults?
  41. Parent training and behavioral interventions examples:
  42. Growth adverse effects of stimulants
  43. When considering ADHD it is important to rule out _____.
  44. The desired outcomes of treatment must be _____.
  45. Side effects of IR clonidine?
  46. 2 "classes" of pharmacological therapy for ADHD
  1. a Sudden unexplained death has been added to ADHD stimulant drug labeling
    - Increased heart rate
    - Increased BP
    - Caution in patients with known cardiac abnormalities
    - Consider baseline ECG if history suggests cardiac abnormality
  2. b - Block dopamine and norepinephrine reuptake
    - Increase catecholamine release
    - Inhibit monoamine oxidase
  3. c Specific
    (e.g. be able to sit an a chair for 20 mins, completes homework assignments)
  4. d Combination of behavioral therapy and pharmacological therapy
  5. e 7 years of age
  6. f - Dose dependent sedation
    - Hypotension
    - Constipation
  7. g - Convenient
    - Better medication adherence
    - Lower cost
    - Less insomnia
    - Potentially fewer growth effects
  8. h Last
  9. i Vyvanse
  10. j Psychosis/Mania
    Aggression or violent behavior
    Severe anxiety/panic attacks
    Tactile hallucinations
  11. k Sugar
    Artificial sweeteners
  12. l Positive rewards for good behavior and structured limit setting are considered first line before meds in ages 3-5
  13. m Delayed release drugs
    (Once-daily formulations are preferred)
  14. n True
  15. o - ADHD stimulants can effect growth, but the effects are minimal/insignificant in children
    - Amphetamines may be associated with more growth effects than methylphenidate
    - Children should be given a drug-free trial every year
    - Not considered a contraindication
  16. p 1. Amoxetine
    2. Central Alpha-2 Adrenergic agonists
    3. Bupropion
    4. Venlafaxine
    5. TCAs
  17. q False
  18. r Stimulants
    Non-stimulants
  19. s - GI upset
    - Psych/ cardiac side effects
    - Warning for severe liver injury
    - Fatigue, sedation
    - FDA warning for new-onset suicidality
  20. t Stimulants
  21. u - Nausea
    - Rash
    - Should not be used in children (or any patient) with seizure disorder or eating disorder
    - May exacerbate tics
  22. v SNRI
  23. w Amoxetine
  24. x Chronic
    No cure
    (requires ongoing management)
  25. y Hyperthyroidism
  26. z Psychotherapy
    - Educational
    - Cognitive
    - Behavioral
  27. aa Guanfacine ER (Tenex)
    Clonidine ER (Catapres)
  28. ab - Iron
    - Zinc
    - Omega 3
    - Additive/Preservative- Free diet
    - Oligoantigenic elimination diet
  29. ac Inhibit NE release presynaptically
    Increase blood flow to the PFC postsynaptically
  30. ad 4-8
  31. ae Behavioral interventions
  32. af - Imipramine
    - Despiramine
    - Nortriptyline
  33. ag 1. Inattention
    2. Hyperactivity and impulsivity
  34. ah Strattera
  35. ai - Weak DA and NE re-uptake inhibitor
    - No significant effect on 5-HT or MAO
  36. aj 1. Methylphenidate
    2. Dexmethylphenidate
    3. Adderal
    4. Dextroamphetamine
    5. Lisdexanfetamine
  37. ak Wellbutrin
  38. al 6+ for at least 6 months
    MUST negatively impact social/ other activities
  39. am 6+ for at least 6 months
    MUST have negative impact on activites
  40. an Non-stimulants
  41. ao Class II
  42. ap Superior
  43. aq 1. Combined type
    2. Hyperactive/Impulsive
    3. Predominantly inattentive
  44. ar - Bradycardia
    - Syncope
    - Rebound hypertension
    - Heart block
    - Sudden death
  45. as Iron
    Zinc
  46. at - Longer time to onset of effectiveness
    - May provide a smoother blood level compared with extended-release formulations
    - It is intended to pose less abuse potential